Details of R&D Day - 24 July
July 02 2007 - 4:00AM
RNS Non-Regulatory
VASTox plc
02 July 2007
VASTox plc
("VASTox" or "the Company")
VASTOX TO HOST R&D DAY ON 24 JULY 2007 IN LONDON
Oxford, UK, 2 July 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, is planning to hold an R&D day in London on 24 July 2007 for investors,
analysts and members of the press. The programme of presentations will cover
various aspects of VASTox's enhanced drug pipeline, its clinical programmes and
the potential of its zebrafish screening platform, following its recent
acquisitions of MNL Pharma, Daniolabs and Dextra Laboratories.
In addition, Professor Francesco Muntoni, Professor of Paediatric Neurology at
the Hammersmith Hospital, and Dr Paul Goldsmith, a consultant neurologist at
Addenbrookes Hospital, will provide clinical perspectives on the areas of
neuromuscular diseases and Parkinson's disease, respectively.
The event will be held at the offices of Huntsworth Health plc, 8th Floor, 26
Finsbury Square, London EC2A 1SF, beginning at 10.00hrs and followed by a buffet
lunch.
For further information and to register interest in attending, please contact
Mark Swallow, Valerie Auffray or Janine Hagan at Citigate Dewe Rogerson on +44
(0)207 282 1068 or email janine.hagan@citigaterdr.co.uk
A preliminary programme is outlined below:
Dr Richard Storer, Overview of drug portfolio & twin technology platforms
Chief Scientific Officer, VASTox
Dr Paul Goldsmith Parkinson's Disease: Sialorrhoea and Seborrhoea. A
clinicians perspective
Consultant Neurologist, Addenbrookes
Hospital
Dr Nigel Blackburn The clinical development plan for the Parkinson's programmes
Director of Clinical Development, VASTox
Prof. Francesco Muntoni Neuromuscular diseases: a clinical focus
Paediatric Neurologist, Hammersmith
Hospital and Imperial College
Dr Jon Tinsley VASTox neuromuscular disease programmes: a focus on Duchenne
muscular dustrophy
Director of Therapeutic Programmes,
VASTox
Dr Richard Storer A Broad and diverse pipeline: VOX14400, Glaucoma and TB
Chief Scientific Officer, VASTox
Dr Alan Roach Zebrafish: the in vivo advantage
Director of Biology, VASTox
Prof Robert Nash Carbohydrates: an emerging technology for the development of
new drugs
Director of Research, VASTox
(Aberystwyth)
- ends -
For more information please contact:
VASTox
Steven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951
Darren Millington, ACMA, Chief Financial Officer
Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571
Evolution Securities
Tim Worlledge / Bobbie Hilliam / Neil Elliot Tel: +44 (0)207 071 4300
About VASTox plc
VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.
VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.
VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.
The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX
Further information about the company is available at www.vastox.com
This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.
Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUUUWCMUPMURP
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jan 2024 to Jan 2025